Trial Profile
Phase I Study of MLN0128 (TAK-228) (NSC# 768435) in Combination With Ziv-Aflibercept (NSC# 724770) in Patients With Advanced Cancers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary) ; Sapanisertib (Primary)
- Indications Cancer; Neuroendocrine tumours; Ovarian cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- 27 Feb 2024 Status changed from active, no longer recruiting to completed.
- 02 Feb 2024 Planned End Date changed from 20 Jan 2024 to 20 Jan 2025.
- 02 Feb 2023 Planned End Date changed from 20 Jan 2023 to 20 Jan 2024.